Sight Sciences (NASDAQ:SGHT) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Sight Sciences (NASDAQ:SGHT) issued its earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05), FiscalAI reports. The company had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.47 million. Sight Sciences had a negative return on equity of 49.92% and a negative net margin of 46.83%.

Here are the key takeaways from Sight Sciences’ conference call:

• Raised revenue guidance: Q1 results drove Sight Sciences to raise full‑year 2026 revenue guidance to $83M–$89M (up from $82M–$88M), reflecting a return to double‑digit revenue growth across both segments.
• Interventional Dry Eye (TearCare) early traction: TearCare revenue nearly doubled sequentially to $1.4M with ~1,500 SmartLids sold and utilization per active account rising from ~9 to ~16, driven partly by cross‑selling into existing glaucoma accounts.
• Interventional Glaucoma (OMNI) momentum: OMNI delivered $18.3M in Q1 (+7% YoY), marking the third consecutive quarter of year‑over‑year growth, aided by Omni Edge adoption and continued focus on combo cataract and standalone markets.
• Improved financial discipline and cash outlook: Adjusted operating expenses fell ~14% YoY, cash used in Q1 was $7M (down from $11.6M), ending cash was $85M, and management says it can reach cash‑flow breakeven without issuing new equity.
• Patent judgment vs. Alcon: A final judgment upheld ~$55M in past damages plus ongoing 10% royalties on Hydrus sales, but no cash has been received and the ruling is subject to appeal, leaving the timing and cash impact uncertain.

Sight Sciences Trading Up 3.7%

Shares of SGHT traded up $0.20 during midday trading on Friday, hitting $5.49. The stock had a trading volume of 42,673 shares, compared to its average volume of 315,268. The stock’s 50 day moving average is $4.07 and its 200 day moving average is $5.84. The firm has a market cap of $298.38 million, a PE ratio of -7.68 and a beta of 2.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 10.22 and a quick ratio of 9.52. Sight Sciences has a 1 year low of $2.94 and a 1 year high of $9.24.

Insider Activity

In related news, CEO Paul Badawi sold 29,244 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total transaction of $108,202.80. Following the transaction, the chief executive officer directly owned 6,151,156 shares in the company, valued at approximately $22,759,277.20. This represents a 0.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Rodberg sold 7,231 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $3.55, for a total transaction of $25,670.05. Following the completion of the sale, the chief financial officer directly owned 230,939 shares of the company’s stock, valued at approximately $819,833.45. The trade was a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,273 shares of company stock valued at $221,764 in the last quarter. 30.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sight Sciences

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Sight Sciences in the second quarter worth about $67,000. O Shaughnessy Asset Management LLC purchased a new position in Sight Sciences in the 4th quarter worth about $81,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Sight Sciences in the 4th quarter worth about $96,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on SGHT. William Blair reiterated an “outperform” rating on shares of Sight Sciences in a research note on Thursday, March 5th. Cantor Fitzgerald set a $8.00 price objective on Sight Sciences in a research report on Monday, March 2nd. Stifel Nicolaus lifted their target price on Sight Sciences from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. UBS Group dropped their price target on Sight Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a report on Friday, April 10th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.31.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.